Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2001
11/08/2001WO2001083729A2 Vectors for ocular transduction and use thereof for genetic therapy
11/08/2001WO2001083698A2 Compositions and methods for inducing activation of dendritic cells
11/08/2001WO2001083562A2 Hybrid protein and vector encoding the same for inhibition of angiogenesis
11/08/2001WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001WO2001083552A2 Human sez6 nucleic acids and polypeptides
11/08/2001WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001WO2001083543A1 Human wingless-like gene
11/08/2001WO2001083514A2 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof
11/08/2001WO2001083513A2 Antisense modulation of inhibitor of dna binding-1 expression
11/08/2001WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001WO2001083511A1 Method of searching for arteriosclerosis inhibitors and shrinkers
11/08/2001WO2001083490A1 Substituted pyrazole derivative
11/08/2001WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001WO2001083486A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001WO2001083484A1 Pyrano, piperidino, and thiopyrano compounds and methods of use
11/08/2001WO2001083475A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001WO2001083470A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
11/08/2001WO2001083469A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001WO2001083462A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments
11/08/2001WO2001083454A1 Benzosuberonylpiperidine compounds as analgesics
11/08/2001WO2001083450A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001WO2001083445A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/08/2001WO2001083439A2 Novel $g(y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
11/08/2001WO2001083427A1 PPARη MODULATORS
11/08/2001WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001WO2001082940A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001WO2001082923A1 Estrogen receptor modulators
11/08/2001WO2001082920A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
11/08/2001WO2001082918A2 Method for the prevention of apoptosis
11/08/2001WO2001082913A2 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
11/08/2001WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001WO2001082858A2 Novel compounds for the treatment of inflammatory and cardiovascular diseases
11/08/2001WO2001068070A8 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
11/08/2001WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001WO2001037780A8 Urotensin-ii analogs
11/08/2001WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001US20010039438 Method for treating neovascularization
11/08/2001US20010039289 Antagonists; especially sodium salts
11/08/2001US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001US20010039268 New 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them
11/08/2001US20010039262 Methods and compositions for the treatment of cardiac indications
11/08/2001US20010039256 Administering to subject a polypeptide derived from soluble receptor for advanced glycation end product
11/08/2001US20010039038 Novel glucosaminidase
11/08/2001US20010038842 Treating a disease characterized by expression of vascular endothelial growth factor-D (VEGF-D) by a tumor by screening for a VEGF-D expressing tumor, administering a VEGF-D antagonist to prevent binding of VEGF-D to its receptor
11/08/2001DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001CA2408105A1 Novel proteases
11/08/2001CA2408073A1 Nucleic acids encoding a novel regulator of a g protein signaling, rgs18, and uses thereof
11/08/2001CA2408011A1 Splice-region antisense composition and method
11/08/2001CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001CA2407959A1 Human wingless-like gene
11/08/2001CA2407914A1 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
11/08/2001CA2407887A1 Natrium-calcium exchanger protein
11/08/2001CA2407881A1 Vectors for ocular transduction and use thereof for genetic therapy
11/08/2001CA2407799A1 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001CA2407796A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001CA2407746A1 Proteases
11/08/2001CA2407737A1 Regulatory nucleic acid for the abc1 gene, molecules modifying its activity and therapeutic uses
11/08/2001CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001CA2407604A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001CA2407587A1 Ppar.gamma. modulators
11/08/2001CA2407535A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
11/08/2001CA2407418A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001CA2407294A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001CA2405745A1 New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments
11/08/2001CA2405611A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001CA2377629A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/07/2001EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001EP1152002A1 Pyrrole derivatives and cell death inhibitors
11/07/2001EP1151998A1 Estrogen agonists/antagonists
11/07/2001EP1151995A1 Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol
11/07/2001EP1151990A1 Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
11/07/2001EP1151753A1 Preventive and therapeutic agents for arteriosclerosis
11/07/2001EP1151101A1 Prostacyclin-stimulating factor-2
11/07/2001EP1151092A1 Inhibiting formation of atherosclerotic lesions
11/07/2001EP1151089A1 Catalytic molecules
11/07/2001EP1151067A1 Process of converting rendered triglyceride oil from marine sources into bland, stable oil
11/07/2001EP1151012A1 Rhamm antagonist antibodies
11/07/2001EP1150997A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
11/07/2001EP1150994A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
11/07/2001EP1150991A2 Compositions for treating inflammatory response
11/07/2001EP1150982A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a)
1 ... 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 ... 1595